Literature DB >> 21677669

T-cell receptor gene therapy: critical parameters for clinical success.

Carsten Linnemann1, Ton N M Schumacher, Gavin M Bendle.   

Abstract

T-cell receptor (TCR) gene therapy aims to induce immune reactivity against tumors by introducing genes encoding a tumor-reactive TCR into patient T cells. This approach has been extensively tested in preclinical mouse models, and initial clinical trials have demonstrated the feasibility and potential of TCR gene therapy as a cancer treatment. However, data obtained from preclinical and clinical studies suggest that both the therapeutic efficacy and the safety of TCR gene therapy can be and needs to be further enhanced. This review highlights those strategies that can be followed to develop TCR gene therapy into a clinically relevant treatment option for cancer patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21677669     DOI: 10.1038/jid.2011.160

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  17 in total

1.  Protective capacity of virus-specific T cell receptor-transduced CD8 T cells in vivo.

Authors:  Katja Mueller; Anne von Mässenhausen; Ulrike Aichele; Lilian Stärck; Matthias Leisegang; Wolfgang Uckert; Hanspeter Pircher
Journal:  J Virol       Date:  2012-07-11       Impact factor: 5.103

2.  High-throughput identification of antigen-specific TCRs by TCR gene capture.

Authors:  Carsten Linnemann; Bianca Heemskerk; Pia Kvistborg; Roelof J C Kluin; Dmitriy A Bolotin; Xiaojing Chen; Kaspar Bresser; Marja Nieuwland; Remko Schotte; Samira Michels; Raquel Gomez-Eerland; Lorenz Jahn; Pleun Hombrink; Nicolas Legrand; Chengyi Jenny Shu; Ilgar Z Mamedov; Arno Velds; Christian U Blank; John B A G Haanen; Maria A Turchaninova; Ron M Kerkhoven; Hergen Spits; Sine Reker Hadrup; Mirjam H M Heemskerk; Thomas Blankenstein; Dmitriy M Chudakov; Gavin M Bendle; Ton N M Schumacher
Journal:  Nat Med       Date:  2013-10-13       Impact factor: 53.440

3.  A new cloning and expression system yields and validates TCRs from blood lymphocytes of patients with cancer within 10 days.

Authors:  Eiji Kobayashi; Eishiro Mizukoshi; Hiroyuki Kishi; Tatsuhiko Ozawa; Hiroshi Hamana; Terumi Nagai; Hidetoshi Nakagawa; Aishun Jin; Shuichi Kaneko; Atsushi Muraguchi
Journal:  Nat Med       Date:  2013-10-13       Impact factor: 53.440

4.  Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy.

Authors:  Christopher A Klebanoff; Christopher D Scott; Anthony J Leonardi; Tori N Yamamoto; Anthony C Cruz; Claudia Ouyang; Madhu Ramaswamy; Rahul Roychoudhuri; Yun Ji; Robert L Eil; Madhusudhanan Sukumar; Joseph G Crompton; Douglas C Palmer; Zachary A Borman; David Clever; Stacy K Thomas; Shashankkumar Patel; Zhiya Yu; Pawel Muranski; Hui Liu; Ena Wang; Francesco M Marincola; Alena Gros; Luca Gattinoni; Steven A Rosenberg; Richard M Siegel; Nicholas P Restifo
Journal:  J Clin Invest       Date:  2015-12-14       Impact factor: 14.808

5.  Adoptive T-cell Immunotherapy: Perfecting Self-Defenses.

Authors:  Raphaëlle Toledano Zur; Galit Adler; Katerina Shamalov; Yair Tal; Chen Ankri; Cyrille J Cohen
Journal:  Exp Suppl       Date:  2022

Review 6.  Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?

Authors:  Christopher A Klebanoff; Luca Gattinoni; Nicholas P Restifo
Journal:  J Immunother       Date:  2012 Nov-Dec       Impact factor: 4.456

Review 7.  Engineered T cells for cancer treatment.

Authors:  Usanarat Anurathapan; Ann M Leen; Malcolm K Brenner; Juan F Vera
Journal:  Cytotherapy       Date:  2013-11-13       Impact factor: 5.414

Review 8.  Cancer immunotherapies revisited: state of the art of conventional treatments and next-generation nanomedicines.

Authors:  Coral García-Fernández; Anna Saz; Cristina Fornaguera; Salvador Borrós
Journal:  Cancer Gene Ther       Date:  2021-04-09       Impact factor: 5.987

9.  Molecular insights for optimizing T cell receptor specificity against cancer.

Authors:  Michael Hebeisen; Susanne G Oberle; Danilo Presotto; Daniel E Speiser; Dietmar Zehn; Nathalie Rufer
Journal:  Front Immunol       Date:  2013-06-19       Impact factor: 7.561

Review 10.  T-Cell Receptor-Engineered Cells for the Treatment of Hematologic Malignancies.

Authors:  Nasheed M Hossain; Aude G Chapuis; Roland B Walter
Journal:  Curr Hematol Malig Rep       Date:  2016-08       Impact factor: 4.213

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.